A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with diastolic heart failure lose weight.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• Diagnosis of heart failure (HF) per the ACC/AHA guidelines with NYHA class II-III symptoms
• Left ventricular ejection fraction \>= 45% within 6 months of recruitment
• At least one of the following: elevated N-terminal pro- B-type natriuretic peptide (NT-proBNP) \>=200 pg/ml (\>=600 pg/ml with concurrent atrial fibrillation), evidence of structural heart disease (left atrial (LA) enlargement with LA volume index \>29 mL/m2 or LA diameter \>=40 mm in males/\>38= mm in females), elevated filling pressures (resting wedge \>15 mmHg or exercise wedge \>25 mmHg, lateral E/e' ratio \>12 or septal E/e' \> 15)
• Body mass index (BMI) \>30 kg/m2
• Stable doses of HF medications within 4 weeks of screening with optimal volume control in the opinion of the investigator.

Key exclusion criteria

• Acute decompensated HF within 4 weeks of screening
• Major cardiovascular event within 90 days of screening (myocardial infarction, stroke)
• Alternate cause of HFpEF such as cardiac amyloidosis, infiltrative cardiomyopathy, hypertrophic cardiomyopathy, severe valvular disease
• Estimated glomerular fibrilation rate (EGFR) \<15 ml/min/1.73m2 or dialysis dependence
• Poorly controlled diabetes (A1c \> 9.5%) OR any type 1 diabetes mellitis